After readjng the article "improved Hydrodynamics fi,,· US P Appflratus 2"(6) T was disma yed that the authors seemed to have confused the concept of "chanhre" with that of"improvcmcnt." If onJy the alteratio n of the des ign of the standard di sso luti o n vessel had (a) removed the effect of "deaeration " as they claim without (b) altering the rate of dissolution , then perhaps the alteration would indeed have been an improvement; but ne ither was shown to be the casc.
1 do agree that" USP Apparatlts 2 (paddle 1IIetbo") bas become tbe wo,-kborse instrulIIe11t i11 tbe 1ll0de771 dissolfltiol1llfborlftory" and that "it is expected to provide 1"uggetland nproducible ' remits, 011 wbicb decisio11s about product qUlflity, bioavailability, bioeqllivalcnce, etc. are blfsed." I-Iowever, I must object to the authors' statements:
• "in practice, tbe appamtlls tends to be extremely sensitive 10 outside I/Ud inside vlwiables, with la1"ge cbanges il1 dissoluti01l profiles reslllti1lgfirrm small cbanges in flfctors such as paddle '"O /lItiol1al speed, vibration, delleratioll lIud insertion of slImpling probes (1,2)"
• "dissolution testing is usually regarded as '11otbing lII01'e tbl/Il a mandlfted 'sC1"vice tool' of questio11able pC1fo17llaIlCC used only to satisfy 1'egulat01Y ,"equirelllcnts, llItbC1'lbl/n II pmve1ful ploedictive tool for pbm7l1!lcclltical "esearcb and {iL'Velop'lJlellt (3) ."
As an analytica1 chemist with more than 10 years of experience in dissolution testing, J have fOWld that tile chi ef sources of variability have been, in order of frequen cy and importance,:
1. 'n e variability in rl,e individual d0&1ge fonns being tested, 2. Failure to perform the studi es exactl y the same way (prin cipally variation in the preparation of tile dissolution media or deaeration differences or both), 3. Lllproper setup of the system (shaft posi-tioning, shaft centering, bent shafts, vessels left uncovered, bath level low, etc.) and 4. Controllable instrument fuctors (vibration, temperature inhomogeneity in me bath, speed em",;
and fluctuations, improper positioning of the heater discharge in "in the bath" designs, etc.). With respect to utility, in addition to being a good indicator of dosage-form performance for the setting of expiration dates from stability test data in the development of new drugs, dissolution testing is a key to detemlining rl,e equivalence of dosage fomlS made by different manufacturers or processes. It is critical to establishing that manufacturing process changes, excipient changes and other minor formulation changes have not changed the delivery of the active ingredient. The view that dissolution testing is "nothing more thltn a mondllted 'service tool''' ignores the fact that the acceptance of dissolution testing by regulatory agencies in the United States and abroad was based on dissolution testing's proven ability to be a surrogate for dosage-form delivery performance. Lacking this tool, pharmaceutical manufacturers would need to do some form of bio-equivalence testing to establish (a) that dosage-form changes do not affect the delivery performance of the finished dosage form or (b) packaging, storage, and time srudies needed to set valid expiration dating.
Dynamics
As recent dissolution studies by W.1ng and Coffin (4) have shown, the rotation speed of 50 rpm for «1blet dissolution can create cones of materials on the bottom of the vessel. These "cones" are the result of the fluid flow present in USP cylindrical, hemispherically bottomed vessels. In cases where tablet disintegration is the key variable controlling dissolution, the build up of the disintegrated particles around the central tablet core does shield the bulk core from the bulk flow of the medium being used in a manner that can retard the dissolution of the active ingredient or ingredients.
The new PEAK (5) vessel does eliminate the possibility of a central cone. The new PEAK vessel has a cone molded into the bottom that causes disintegrating materials to be dispersed into a ring around the molded in cone. In effect, this "molded in cone" displaces the center and causes "disintegrating particles" to be dispersed into a ring around the "cone" which, for a given mass of disintegrated material is larger in area and, of necessity, thinner than the cone of similar material in the USP vessel. In addition, because of the turbulence generated, the tablets tumble around the "molded in cone" much more vigorously than they do in the center of the USP vessel. Finally, positioning the shafts in the PEAK vessels at the distance from the bottom of the molded in peak to meet the USP requirement for placement decreases the effective average distance between the bottom of the active region of the paddle to the top of the dosage wut being tested because they are displaced towards the tips of the paddle blade and cannot reside in the center, the region of least turbulence.
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Given all of the preceding differences, one would predict that the PEAK vessel could give higher values than the USP vessel because of the obviously stronger energy transfer mechanisms for the PEAK vessel. Thus, "tbe glass cone effectively displaces tbe unstilTed Cfme,forci'llg tbe mllten!" tested into" a region of different dynamics, where all surfaces of the product are more exposed to the moving meruwn and to interactions with the tumbling tablet.
Therefore, the PEAK vessel ' s shape changes not only the hydrodynamics of the vessel but also the dynam.ics of the tablet IllOtiOll, the average proxinury of the tablet to the paddle, and, for disintegrating tablets, the dynamics of the interaction of the bulk of the tablet with the disintegrated portions of the tablet. The commentary which follows will attempt to evaluate the data presented in the article "Improved HyclroclY17aUlicsfor USPApparntus 2" (6).
Influence of Deaeration
In "Fig" ure 3 ," the article reports data for studies using two test conditions, liD" and "ND," in both labs using a non-USP "standard" tablet, "FDA Prednjsone NCDA#2 10 mg Tablets" (a disiJ1te-grating tablet), 500 mL of "water" and 50 rpm with sampling at 30 1l1inutes. The two test conditions correspond to using "deaerated water" ("0") or to using "nondeaerated water" ("ND") as dle dissolution media. However, the article does not state the sources of the water used, its quality, the procedure used by each lab to "deaerate" the water, or the measures of the quality of the water. In " Figure 3 ," the first fact seems to be that when using the PEAK vessels both labs obtained results "similar" to the results obtained by "Lab 2" in the "ND" case. When using the USP vessels and the PEAK vessels, both labs obtained lower average results using "deaerated water." Because all of the data for the PEAK vessel cases was close to the point that the available drug has completely dissolved (> 80 % "released"), the differences between the "0" cases and the ''ND'' cases are small. Because the data for dle "0" cases using the USP vessels were at values indicating that less DissollltiollTecimologiesl AUGUST 1996 than 45 % of the available drug had dissolved and the "ND" values were in the "50+ to 90%" range, the differences seen were much larger when the USP vessels were used. Nonetheless, the "D" values were less than the "ND" values for both the PEAK and the USP vessels. Before any valid conclusion could be drawn as to whether or not the PEAK vessel significantly reduces the "deaerarion" effect, the sampling time on the PEAK vessels would need to have been reduced until the "% dissolved" values were less than 50% for the "0" cases. In the absence of such data and without replication of at least the "0" experiment in each lab, the data do not support tl,e footnoted statement that tl,e deaerarion has "twgligible iujlueuce on tbe Peak vessels."
In "Figtn~ 4," tl,e article reports data for snldies using the same two test conditions, "0" and "ND," in the same two labs and the USP disintegrating caJjbrator tablet, "USP Prednisone Calibrator 50 mglablets", using 900 mL of water, 50 rpm, and sampling at 30 minutes. The two test conditions correspond to using "deaerated water" ("0") or to using "nondeaerated water" ("ND") as the dissolution media. Based on the data presented in " Fig/we 4," clle use of the PEAK vessels did not produce results that indicate any acceleration or increase of dissolution over the USP vessel. Yet clle article does not address or explain why this was clle case. Moreover, there appears to be a small "deaeration" effect for the USP vessels in both labs and "Lab 2" for the PEAK vessels; but no apparent effect in "Lab I" using the PEAK vessels. Given that about 50 to 60% of the 50 mg of drug was measured under this test condition in 900 mL of water and that there was not a significancly larger value for experiments using the PEAK vessel, then about 15 mg of Prednisone could have dissolved if the volume were reduced to 500 mL. This con fi nllS that the values above 80% in clle " Figure 3 " experiments probably represented almost complete solubiliz.1tion of the available Prednisone ill d,e PEAK vessels at 50 rpm after 30 minutes.
In "Figtwe 5," the article reports data for studies using clle same two test conditions, "0" and "ND" in the sa m e two labs using the USP non-disintel,'Tati ng Sa li cylic Acid 300 mg CalibratOr tablets 900 mL of 0.05 M phosphate buffer at pH 7.4, and 50 rpm with sampling at 30 minutes. T he two test conclitions correspond to using "deaerated buffer" ("D") o r to usin g " nondeaerated buffer" ("ND") as the dissolution media. Based on the data presented in "FigliH S," without any replication data, all d,at should be said is that, in th is case, the use of d,e PEAK vesse ls did produce results t hat indicated an accele rati o n or increase of dissolution over the USP vesse l. In addition , t he re did not appea r to be a significant " 0" effect for either d,e PEAK vessels in bod, labs and "L1b 2" for the USP vessel [there is no data "ND" for "Lab I " in this figure].
SUlllm ari zi ng the a rticle's data o n the influence of deaeration , it seems that using the PEAK vessels prod uces hi g her va lues for both di sintegrating and non-disintegrating tablets provided the solubility of the drug is not near the solution's capacity. Claims as to the lack of effect of"deaeration" have not been substantiated. Given the h igh er values, the autho rs shou ld have red uced the time va riable until the m ean va lu es obse rved for the PEAK vessels "0" experiments " m atch ed" t hose of the USP vessels a nd th en reported the "0" and "ND" va lues at that time an d compared those to t he "D" and "ND" val ues at 30 minutes in the USP vessels.
Influence Df Stirring Speed
In " Figure 6 ," the article reports data for stud ies using three rpm va lu es, 50, 75, and 100, in "Lab I " and a non-USP "srandard" tablet, "FDA Prt.-·dnlsone NCDA#2 10 mg l "lblets" (a disintegrating tablet), using 500 mL of "de aerated water," and sampling at 30 minutes. G iven (Figure 3) that th e previous data s h ow t h at t h e 1 O-mg Prednisone tablets are "comp lete ly" dissolved at 50 rpm in the PEAK vessels, then in creasing the stirring speed should, as it does, have no effect. When a tablet is "completely" dissolved under a fixed time/media/speed condition , then increasing the speed will nOt affect the am o unt dissolved and t h e variations will be those arising from product inhomogeneity and measuring flucnJa tions. T herefore, as designed, the results of the speed study using the PEAK vessel should not, and did not show any "stirrin g speed" effect. Based on th e data for th e USP vesse ls, it appears that as o ne increases the speed sign ifi cantly, the dissolution increases significantly also. For d,is study to add ress d,e issue raised in the article of "Imge c/Jrmges ill dissolution profiles 1'esllltingfrom smnll cbflnges il1 pnddle 1'Oftlfiollfti speed," then it wou ld have studjed profiles at times where the tablet is not dissolved completely with small perturbations in rpm (for exa mpl e, 48, 50, 52 rpm), randomi zatio n , triplicate o r morc experiments at each speed, recovery controls, f0I11131 experimental designs, and statistical eva luation to ascertain th e difference in results, va lidl y attrib utable to the speed of rotation.
rn " Figure 7 ," the article reports data for sUldies using three rpm values, 50, 75, and 100, in "Lab I" using d,e USP non-disintegrating calibrator tablet, "USP Altered Dynamics ... cont.
Salicylic Acid Calibrator 300 mg 1ablets" and 900 mL o f 0.05 M phosphate buffer at pH 7.4 with sampling at 30 minutes. In this case, the PEAK vessels gave higher results at every speed than the USP vessels. T he data from the PEAK vessels also appears to reach a maximum at 75 rpm. TllOugh lower, the apparent "average" va lues for the USP test seem to be the "same" at all rpm levels (but only 4 va lues appear to have been reported at 75 rpm). In neither case is th ere a large "rpm" effect. The o nl y fa ct that is dearly supported is that the PEAK vessels give higher va lues than the USP for a 30-minute sampling time Of , in the authors' words, "datn also indicates tbat disso/utio11 is more complete in PEA K vej:rels cO'Iltpllred to tbe conventio11al cyli11lh-icnl type."
Summarizing the article's data on the influence of the stirring speed, use of PEAK vessels does indeed produce hi gher values for both disintegrating and non-d isintegrating ta bl ets provided the solubility of the drug is not near the solution's capacity.
Excellent Correlation to Dissolution Results Using USP Apparatus 3
The articl e's data as presented in Figures 8,9 & 10 did show that the reported dissolution resul ts obta in ed from PEAK vessels using Apparatus 2 correlated closely with those from Apparatus 3. I-Iowever, the failure: (3) to use a "spiral wi re sinker" for all of cl,e USP 2 tests, (b) to make certa in that cl,e p1-1 of the media was 1.0 when the tests were done using the PEAK vessels, (c) to address the problem of much lower results obtained for the PEAK vessels (P I) when the tablets were all owed to be stuck in one posicion for 6 to 8 hours, and (d) to define the time and method for loosening dle mblets in "P2" and "P3" experiments precludes any other va lid conclusions from be ing reached.
I-Iowcver, are higher rates and good correlation between USP 3 and USP 2 desir.,ble? If so, cl,en why not simply move the paddle closer to the bottom?
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No Influence of Sampling Probes
In the absence of any data addressi ng the influence of sampling probes with the P EAK vessel, the authors' claim of "no influence of sampling poin ts" is not justified.
PEAK Vessels and USP Calibrators
The authors propose chan ging cl,e USP's set of specifications, calibrators, and vessels to an as yet wldefined P EAK set as the solution to the dissolution differences between resu lts obta ined using PEAK vessels and t hose obta in ed using USP vessels. J-Iowever, the conconutant problems of changing the limits, times, or rpm, or combinations thereof for aJ I of the existi ng products and the dislocations such a change as this wou ld introduce are ignored. Based on a consideration of all that would need to be done to cha nge from the US!' vesse ls to t he PEAK vessels, it see ms that more problems wou ld be generated than this change purports to solve.
Conclusions
The use of cl,e PEAK vessels alters cl,e dynamics of the present USP 2 dissolution system. O ther than an increase in the va lues obselved at a given IXlint in time below dle component saruration point, none of the claims made by the authors for the PEAK vessel in comparison to the US P vesse l have been substantiated by cl,e data they ha ve presented.
